{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:14:36Z","timestamp":1791357276160,"version":"4.3.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.schres.2015.08.027","type":"journal-article","created":{"date-parts":[[2015,9,12]],"date-time":"2015-09-12T07:57:35Z","timestamp":1442044655000},"page":"22-29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"title":["Antipsychotic treatment reduces psychotic symptoms and markers of low-grade inflammation in first episode psychosis patients, but increases their body mass index"],"prefix":"10.1016","volume":"169","author":[{"given":"Liina","family":"Haring","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kati","family":"Koido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veiko","family":"Vasar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vambola","family":"Leping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kersti","family":"Zilmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihkel","family":"Zilmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eero","family":"Vasar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2015.08.027_bb0005","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S0165-0173(99)00046-6","article-title":"Serotonin model of schizophrenia: emerging role of glutamate mechanisms","volume":"31","author":"Aghajanian","year":"2000","journal-title":"Brain Res. Brain Res. Rev."},{"key":"10.1016\/j.schres.2015.08.027_bb0010","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.schres.2013.03.027","article-title":"Antipsychotics can modulate the cytokine profile in schizophrenia: attenuation of the type-2 inflammatory response","volume":"147","author":"Borovcanin","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2015.08.027_bb0015","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1037\/0033-2909.98.3.569","article-title":"Season of birth in schizophrenia: a review of evidence, methodology, and etiology","volume":"98","author":"Bradbury","year":"1985","journal-title":"Psychol. Bull."},{"key":"10.1016\/j.schres.2015.08.027_bb0020","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/B978-0-12-387718-5.00005-5","article-title":"Converging evidence of blood-based biomarkers for schizophrenia: an update","volume":"101","author":"Chan","year":"2011","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.schres.2015.08.027_bb0025","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/schbul\/sbj028","article-title":"The role of obstetric events in schizophrenia","volume":"32","author":"Clarke","year":"2006","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2015.08.027_bb0030","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1136\/jmg.2005.030718","article-title":"The genetics of schizophrenia and bipolar disorder: dissecting psychosis","volume":"42","author":"Craddock","year":"2005","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.schres.2015.08.027_bb0035","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/j.2051-5545.2009.tb00199.x","article-title":"Metabolic syndrome in people with schizophrenia: a review","volume":"8","author":"De Hert","year":"2009","journal-title":"World Psychiatry"},{"key":"10.1016\/j.schres.2015.08.027_bb0040","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.schres.2014.02.005","article-title":"Cytokine alterations in first-episode schizophrenia patients before and after antipsychotic treatment","volume":"154","author":"De Witte","year":"2014","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2015.08.027_bb0045","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.bbi.2012.06.010","article-title":"Serum and gene expression profile of cytokines in first-episode psychosis","volume":"31","author":"Di Nicola","year":"2013","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.schres.2015.08.027_bb0050","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1017\/S1461145710001653","article-title":"An activated set point of T-cell and monocyte inflammatory networks in recent-onset schizophrenia patients involves both pro- and anti-inflammatory forces","volume":"14","author":"Drexhage","year":"2011","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2015.08.027_bb0055","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/B978-0-12-387718-5.00007-9","article-title":"Immune and neuroimmune alterations in mood disorders and schizophrenia","volume":"101","author":"Drexhage","year":"2011","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.schres.2015.08.027_bb0060","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1176\/appi.ajp.2009.09060802","article-title":"International consensus study of antipsychotic dosing","volume":"167","author":"Gardner","year":"2010","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2015.08.027_bb0065","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1016\/j.euroneuro.2014.09.011","article-title":"Disruption of the ErbB signaling in adolescence increases striatal dopamine levels and affects learning and hedonic-like behavior in the adult mouse","volume":"24","author":"Golani","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2015.08.027_bb0070","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1440-1711.2005.01305.x","article-title":"Immune dysregulation and self-reactivity in schizophrenia: do some cases of schizophrenia have an autoimmune basis?","volume":"83","author":"Jones","year":"2005","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.schres.2015.08.027_bb0075","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000339866","article-title":"Comparative study of systemic inflammatory responses in psoriasis vulgaris and mild to moderate allergic contact dermatitis","volume":"225","author":"Kaur","year":"2012","journal-title":"Dermatology"},{"key":"10.1016\/j.schres.2015.08.027_bb0080","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2015.08.027_bb0085","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.psychres.2006.06.004","article-title":"T- and B-lymphocytes in patients with schizophrenia in acute psychotic episode and the course of the treatment","volume":"152","author":"Maino","year":"2007","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2015.08.027_bb0090","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0920-9964(01)00254-7","article-title":"One year outcome in first episode psychosis: influence of DUP and other predictors","volume":"54","author":"Malla","year":"2002","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2015.08.027_bb0095","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.schres.2005.07.014","article-title":"Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III","volume":"80","author":"McEvoy","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2015.08.027_bb0100","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","article-title":"Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects","volume":"70","author":"Miller","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2015.08.027_bb0105","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2013.29","article-title":"ErbB inhibitors ameliorate behavioral impairments of an animal model for schizophrenia: implication of their dopamine-modulatory actions","volume":"3","author":"Mizuno","year":"2013","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.schres.2015.08.027_bb0110","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-211-73574-9_33","article-title":"The immunological basis of glutamatergic disturbance in schizophrenia: towards an integrated view","volume":"269\u2013280","author":"Muller","year":"2007","journal-title":"J. Neural Transm. Suppl."},{"key":"10.1016\/j.schres.2015.08.027_bb0115","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2174\/157339510791823673","article-title":"Immune system and schizophrenia","volume":"6","author":"Muller","year":"2010","journal-title":"Curr. Immunol. Rev."},{"key":"10.1016\/j.schres.2015.08.027_bb0120","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.pnpbp.2012.10.022","article-title":"The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia","volume":"48","author":"Na","year":"2014","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2015.08.027_bb0125","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.biopsych.2007.09.024","article-title":"Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review","volume":"63","author":"Potvin","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2015.08.027_bb0130","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/mp.2011.42","article-title":"Identification of a biological signature for schizophrenia in serum","volume":"17","author":"Schwarz","year":"2012","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.schres.2015.08.027_bb0135","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.psyneuen.2013.12.005","article-title":"Increased serum interleukin-6 levels in early stages of psychosis: associations with at-risk mental states and the severity of psychotic symptoms","volume":"41","author":"Stojanovic","year":"2014","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.schres.2015.08.027_bb0140","first-page":"33","article-title":"Gender and schizophrenia","volume":"58","author":"Tamminga","year":"1997","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2015.08.027_bb0145","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.schres.2014.03.005","article-title":"Cytokine function in medication-naive first episode psychosis: a systematic review and meta-analysis","volume":"155","author":"Upthegrove","year":"2014","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2015.08.027_bb0150","series-title":"The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines","author":"World Health Organization","year":"1992"},{"key":"10.1016\/j.schres.2015.08.027_bb0155","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.schres.2014.03.024","article-title":"Decreased interleukin-10 serum levels in first-episode drug-naive schizophrenia: relationship to psychopathology","volume":"156","author":"Xiu","year":"2014","journal-title":"Schizophr. Res."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996415004569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996415004569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T15:59:21Z","timestamp":1568044761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996415004569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":31,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0920996415004569"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2015.08.027","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antipsychotic treatment reduces psychotic symptoms and markers of low-grade inflammation in first episode psychosis patients, but increases their body mass index","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2015.08.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}